Markets
markets
Luke Kawa

US equity futures sink on twin shocks from tariffs and tech

S&P 500 futures are down 1% as of 7:40 a.m. ET, reeling from twin shocks on tariffs and tech.

On Thursday evening, via an executive order, President Donald Trump announced 10% minimum global tariffs, a 15% levy on imports from countries that run trade surpluses with the US, and a 40% tax on goods transshipped in an attempt to duck other tariffs, due to take effect on August 7. There were also a host of hikes to tariff rates on countries that had not struck new deals with the US after the initial Rose Garden tariffs were delayed.

At their lows in premarket trading, the SPDR S&P 500 ETF and Invesco QQQ Trust were down 1.1% and 1.3%, respectively.

As we’ve noted, Trump Always Raises Tariffs (TART) is a more reliable characteristic of the 45th and 47th president’s time in office than the notion that Trump Always Chickens Out (TACO). The US effective tariff rate is poised to go up even more absent any new deals or delays. Bloomberg Economics estimates that these measures will propel the average US tariff rate north of 15%.

Meanwhile, Amazon slumped after delivering an underwhelming outlook for operating profits and some disappointing commentary during its conference call, sending shares as much as 8% lower. When a trillion-dollar company nosedives that much, it’ll usually leave a mark on major indexes.

More Markets

See all Markets
(J. Edward Moreno/Sherwood News)

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

markets

Ozempic is no longer the most-searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be short hand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January more people in the US are searching for Eli Lilly’s weight loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides," a catch-all term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lilly's diabetes and weight loss drugs have outsold Novo's and that gap is expected to widen this year.

markets

Crypto crumble smokes bitcoin-sensitive stocks and speculative tech

It’s a rough day out there, with the pain in the crypto markets being felt among select subgroups of US equities. Shortly before 2 p.m. ET on Wednesday here’s a snapshot of where some of the worst pinches are.

There is some overlap between some of these baskets, for instance bitcoin treasury company Strategy figures both in the “bitcoin sensitive” and “meme” basket. But in general it’s just a pretty ugly day for some of the more speculative corners of the stock market.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.